Preclinical studies and absorbed dose estimation of [ 89 Zr]Zr-DFO-Bevacizumab for PET imaging of VEGF-expressing tumors.

Autor: Zolghadri S; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran., Mohammadpour-Ghazi F; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran., Yousefnia H; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. Electronic address: hyousefnia@aeoi.org.ir.
Jazyk: angličtina
Zdroj: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine [Appl Radiat Isot] 2024 Aug; Vol. 210, pp. 111379. Date of Electronic Publication: 2024 May 28.
DOI: 10.1016/j.apradiso.2024.111379
Abstrakt: This study aimed to carry out the preclinical studies of [ 89 Zr]Zr-DFO-Bevacizumab. The radiolabeled compound was prepared with radiochemical purity >99% (ITLC), and a specific activity of 74 GBq/g. Cellular studies indicated the great capability of [ 89 Zr]Zr-DFO-Bevacizumab for binding to SKOV3 cell lines. High accumulation was observed in the tumor. The liver and spleen received the highest absorbed dose with 1.12 and 0.72 mGy/MBq, respectively. This radiopharmaceutical can be considered as a suitable PET agent for VEGF-expressing ovarian cancer imaging.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Hassan Yousefnia reports financial support was provided by International Atomic Energy Agency. The authors would like to acknowledge the invaluable scientific and financial support of the International Atomic Energy Agency (IAEA) for this research under the Coordinated Research Project (Project Code; F22071, IAEA Research Contract No: 23763) If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: